Clinical trial Recruiting at 2 sites Interventional Ages Any age to 25

Creating immune organoids to study pediatric cancers

Official title: Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)

Run by Gustave Roussy, Cancer Campus, Grand Paris · NCT05890781 · Data updated 2026-11-12

This study is trying to create mini immune systems from kids' tissues to see how they respond to different types of pediatric cancers.

Quick facts

Study typeInterventional
AgesAny age to 25 Years
SexAll
Enrollment108 (estimated)
SponsorGustave Roussy, Cancer Campus, Grand Paris
Academic / other
Locations2 sites (Villejuif and 1 other locations)
StatusRecruiting
StartedMay 12, 2023
Main results expectedMay 2028
Study endsMay 2028
Registry record updatedFebruary 9, 2026
Trial IDNCT05890781 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pediatric patients aged 25 years or younger with a medical suspicion or diagnosis of brain tumors, renal tumors, neuroblastoma, or sarcomas.

Probably not a fit

Patients with histologies not specified in the inclusion criteria or those unable to provide informed consent may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to engineer immune organoids from tissues of pediatric patients using induced-pluripotent stem cells (iPSC). By utilizing skin biopsies, fresh tumor samples, blood samples, healthy tissue, and cerebrospinal fluid, the research seeks to better understand the immune response in various pediatric cancers, including brain tumors, kidney tumors, neuroblastoma, and sarcomas. The approach focuses on leveraging patient-derived materials to create organoids that can mimic the tumor environment and immune interactions. This innovative methodology may provide insights into treatment responses and disease mechanisms.

Why it matters

Potential benefit: If successful, this research could lead to improved understanding and treatment strategies for pediatric cancers.

How similar studies have gone: While the approach of engineering immune organoids is innovative, similar studies have shown promise in understanding cancer biology and treatment responses, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
* Medical suspicion or diagnosis of one of the following diseases, regardless of stage:
* Brain tumors
* Renal tumors
* Neuroblastoma
* Sarcomas
* Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
* Affiliated to a social security system or beneficiary of the same.

Exclusion Criteria:

* Any histology not mentioned in the inclusion criteria
* Adult patient or parents/guardians incapable/incapable of giving its/their consent
* Patients deprived of their liberty by a judicial or administrative decision

Where it's running

  • Gustave Roussy
    Villejuif, France
    Recruiting
  • Hopital Necker
    Paris, Île-de-France Region, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.